EFM
BCRX icon

E Fund Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

E Fund Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$375K Sell
37,452
-7,080
-16% -$64K 0.01% 340
2026
Q1 		$424K Buy
+44,532
New +$346K 0.01% 320
2025
Q2 		$301K Buy
33,592
+9,918
+42% +$92.4K 0.01% 302
2025
Q1 		$178K Buy
23,674
+7,062
+43% +$57K 0.01% 370
2024
Q4 		$125K Sell
16,612
-7,226
-30% -$54.9K 0.01% 376
2024
Q3 		$181K Sell
23,838
-4,447
-16% -$33.8K 0.01% 336
2024
Q2 		$175K Sell
28,285
-45,895
-62% -$253K 0.01% 298
2024
Q1 		$377K Buy
74,180
+22,863
+45% +$129K 0.02% 236
2023
Q4 		$307K Buy
51,317
+9,820
+24% +$56.9K 0.02% 228
2023
Q3 		$294K Sell
41,497
-10,926
-21% -$78.5K 0.02% 213
2023
Q2 		$369K Buy
52,423
+5,838
+13% +$46.8K 0.03% 190
2023
Q1 		$389K Buy
46,585
+6,330
+16% +$60.9K 0.03% 175
2022
Q4 		$462K Buy
40,255
+4,838
+14% +$60.3K 0.04% 145
2022
Q3 		$446K Sell
35,417
-8,991
-20% -$116K 0.04% 146
2022
Q2 		$470K Buy
44,408
+27,767
+167% +$286K 0.04% 154
2022
Q1 		$271K Buy
16,641
+1,756
+12% +$28.2K 0.01% 233
2021
Q4 		$206K Buy
14,885
+3,536
+31% +$46.8K 0.01% 256
2021
Q3 		$163K Buy
+11,349
New +$179K 0.01% 242
2021
Q1 		$112K Buy
+10,970
New +$113K 0.01% 236

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

E Fund Management's BCRX Position: Q2 2026 in Review

E Fund Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 16% in Q2 2026, selling an estimated $64K and leaving 37,452 shares worth $375K. The position accounts for 0.01% of the portfolio, ranked #340.

E Fund Management first reported a position in BCRX in Q1 2021 and has held it in 19 quarters since. The position peaked at $470K in Q2 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • E Fund Management held 37,452 shares of BioCryst Pharmaceuticals worth $375K as of Q2 2026.
  • E Fund Management sold 7,080 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $64K.
  • BioCryst Pharmaceuticals made up 0.01% of E Fund Management's portfolio in Q2 2026, its #340 holding.
  • E Fund Management first reported a position in BioCryst Pharmaceuticals in Q1 2021 and has held it in 19 quarters since.
  • E Fund Management's BioCryst Pharmaceuticals position peaked at $470K in Q2 2022.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.